AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie recorded Litigation Accrual Reserve ($M) ($M)
Form 10-Q / 10-K Legal Proceedings & Contingencies Note
Latest, FY2025
1,600
Period ended Dec 31, 2025
Change on a year earlier
-36.0%
2,500 in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Recorded Litigation Accrual Reserve ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,600 | -36.0% | Form 10-Q (filed 2026-08-03) ↗ |
| FY2024 | Dec 31, 2024 | 2,500 | +25.0% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 2,000 | – | Form 10-K (filed 2025-02-14) ↗ |
Breakdown
What makes up recorded litigation accrual reserve ($m)
- Net Litigation Reserve Charges / Adjustments ($M)-933 · FY2025
- Pending Legal Claims — Prescription Opioid Lawsuits Total (cases)335 · FY2025
- Pending Legal Claims — Biocell Textured Breast Implant ALCL State Lawsuits (cases)75 · FY2025
- Pending Legal Claims — Other Product Liability Lawsuits (cases)1,320 · FY2025
- Pending Individual Lawsuits — Niaspan Antitrust [annual] (cases)6 · FY2025
Cite this data
StockData. (2026). AbbVie Recorded Litigation Accrual Reserve ($M) ($M), annual FY2023–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/lit_reserve_tot
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.